Clin Psychopharmacol Neurosci.  2016 Nov;14(4):345-350. 10.9758/cpn.2016.14.4.345.

Evaluation of Paraoxonase, Arylesterase and Malondialdehyde Levels in Schizophrenia Patients Taking Typical, Atypical and Combined Antipsychotic Treatment

  • 1Department of Psychiatry, Faculty of Medicine, Dicle University, Diyarbakir, Turkey.
  • 2Department of Psychiatry, State Hospital of Afsin, Kahramanmaras, Turkey.
  • 3Department of Biochemistry, Faculty of Medicine, Dicle University, Diyarbakir, Turkey.


OBJECTIVE: Human serum paraoxonase (PON1) prevents lipids from peroxidation and functions as an antioxidant mechanism. Malonyldialdehyde (MDA) is the final product of lipid peroxidation and can be used as an indicator of oxidative stress. The aim of this study was to investigate PON1, MDA, and arylesterase (ARY) levels in schizophrenic patients who are taking typical, atypical, or combined (typical and atypical) antipsychotic drug treatment, with respect to those of healthy controls.
We evaluated 41 patients (11 taking typical antipsychotics, 19 taking atypical antipsychotics, 11 taking combined anti-psychotics) and 43 healthy controls.
MDA levels were higher in schizophrenic patients taking typical antipsychotics compared with healthy controls (p=0.001). ARY levels were higher in patients taking atypical antipsychotics compared with healthy controls (p=0.005). PON1 activity was similar in all groups.
Our results indicate that treatment with typical antipsychotic drugs could be related to increased MDA levels; and antipsychotic medication may increase PON1 levels in schizophrenic patients.


Paraoxonase; Arylesterase; Malondialdehyde; Schizophrenia; Antipsychotics; Treatment
Full Text Links
  • CPN
  • Twitter
  • Facebook
Copyright © 2020 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: